Iridex Corporation filings document an ophthalmic medical technology issuer whose disclosures center on laser systems, delivery devices, consumables, and procedure probes for glaucoma and retinal disease applications. Form 8-K reports furnish operating and financial results, preliminary results, Regulation FD investor materials, material agreements, and other material-event disclosures.
Proxy materials describe board matters, executive compensation, equity award valuation adjustments, and pay-versus-performance information. The filing record also includes Nasdaq continued-listing compliance updates, capital-structure context such as stockholders’ equity requirements, exhibits to press releases and presentations, and Inline XBRL cover-page data for formal Exchange Act reporting.
IRIDEX Corp’s Chief Financial Officer, Romeo R. Dizon, reported an open-market purchase of company stock. On March 6, 2026, he bought 1,110 shares of IRIDEX common stock at $1.26 per share. Following this transaction, his direct holdings increased to 121,000 shares.
Dizon Romeo R reported open-market purchase transactions in a Form 4 filing for IRIX. The filing lists transactions totaling 2,200 shares at a weighted average price of $1.34 per share. Following the reported transactions, holdings were 119,890 shares.
IRIDEX Corp’s Chief Financial Officer, Romeo R. Dizon, bought company stock in the open market. On 02/12/2026, he purchased 1,500 shares of IRIDEX common stock at a price of $1.43 per share in a direct transaction.
Following this purchase, Dizon directly beneficially owned 117,690 shares of IRIDEX common stock. The filing records this as an open-market purchase under the standard insider transaction reporting rules.
IRIDEX Corp’s Chief Financial Officer, Romeo R. Dizon, reported an open-market purchase of common stock. On 02/10/2026, he acquired 1,000 shares of IRIDEX common stock at a price of $1.46 per share.
Following this transaction, Dizon directly beneficially owned a total of 116,190 shares of IRIDEX common stock. The filing indicates the ownership is held directly, and the Form 4 was signed on his behalf by attorney-in-fact Nilo De Castro.
IRIDEX Corp's Chief Financial Officer, Romeo R. Dizon, reported a stock purchase in a Form 4 filing. On 02/03/2026, he acquired 2,500 shares of IRIDEX common stock at a price of $1.38 per share. Following this transaction, he directly owns 115,190 common shares.
IRIDEX Corporation’s Chief Financial Officer, Romeo R. Dizon, reported buying additional company stock. On January 29, 2026, he purchased 1,101 shares of common stock at $1.442 per share, bringing his directly held stake to 112,690 shares.
IRIDEX Corporation’s Chief Financial Officer, Romeo R. Dizon, reported an open-market purchase of company stock. On January 28, 2026, he bought 1,300 shares of common stock at $1.46 per share. Following this transaction, he directly owns 111,589 shares of IRIDEX common stock.
IRIDEX Corporation’s Chief Financial Officer, Romeo R. Dizon, reported an open-market purchase of company stock. On 01/27/2026, he bought 3,385 shares of Common Stock at a price of $1.4799 per share, as shown by transaction code "P" for a purchase. Following this transaction, he beneficially owns 110,289 shares of IRIDEX Common Stock in direct ownership.
IRIDEX Corp Chief Financial Officer buys additional shares. On 01/26/2026, CFO Romeo R. Dizon purchased 1,243 shares of IRIDEX common stock at $1.52 per share in an open-market transaction coded "P" (purchase). After this trade, he directly owned 106,904 shares of IRIDEX common stock. This filing reflects a change in his personal share ownership and does not describe any change in the company’s operations or financial results.
IRIDEX Corporation’s Chief Financial Officer, Romeo R. Dizon, purchased additional shares of the company’s common stock. On 01/23/2026, he bought 5,221 shares at a weighted average price of $1.4779 per share, with individual trade prices ranging from $1.475 to $1.48. Following this purchase, he beneficially owns 105,661 shares of IRIDEX common stock in direct ownership. The transaction was reported as an open-market or private purchase, with full trade-level pricing details available upon request from the company, its security holders, or the SEC staff.